Pauline Nguyen
Adult Health · Southlake, TXNPI 1336419720
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,792 of the $22,563 with a category attached, or 65.6%. 32 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 32.3% of the total. Reporting peaked in 2022 at $10,514 and has fallen 98.6% since, to $148 in 2025. Among adult health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 839 payments — averaging $26.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$7K
- AbbVie$5K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Daiichi Sankyo Inc.$1K
- Pfizer$860
- plus $6K from 26 others
What the payments were for
- Consulting fees$6,00027%
- Travel & lodging$1,5297%
- Food & beverage$14,79266%
- Education$2421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 14 | $7,278 |
| AbbVie | 202 | $4,631 |
| Johnson & Johnson | 33 | $1,791 |
| Takeda Pharmaceuticals U.S.A., Inc. | 102 | $1,332 |
| Daiichi Sankyo Inc. | 109 | $1,149 |
| Pfizer | 59 | $860 |
| Bristol Myers Squibb | 57 | $842 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 61 | $842 |
| Intercept Pharmaceuticals, Inc. | 18 | $421 |
| Nestle Healthcare Nutrition Inc. | 24 | $350 |
| Merck | 20 | $329 |
| Redhill Biopharma Inc. | 30 | $291 |
| Lilly USA, LLC | 10 | $286 |
| Sanofi | 7 | $270 |
| Regeneron Healthcare Solutions, Inc. | 11 | $263 |
| Ironwood Pharmaceuticals, Inc | 12 | $253 |
| QOL Medical, LLC | 13 | $246 |
| Aimmune Therapeutics, Inc. | 8 | $206 |
| Evoke Pharma, Inc. | 11 | $194 |
| Braintree Laboratories, Inc. | 4 | $108 |
| Boehringer Ingelheim | 4 | $92 |
| Fresenius Kabi USA, LLC | 4 | $78 |
| Organon | 7 | $77 |
| Amgen | 3 | $72 |
| Gilead | 4 | $63 |
| Ferring Pharmaceuticals Inc. | 3 | $58 |
| Ardelyx, Inc. | 3 | $53 |
| AstraZeneca | 2 | $39 |
| Abiomed | 1 | $33 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Vivus LLC | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,563 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 13 | $73,787 |
| LinzessLinaclotide | 38 | $52,072 |
| Dexlansoprazole DrDexlansoprazole | 43 | $18,460 |
| Mesalamine | 19 | $16,594 |
| Pantoprazole Sodium | 302 | $3,987 |
| CholestyramineCholestyramine (With Sugar) | 25 | $2,912 |
| NexiumEsomeprazole Magnesium | 11 | $2,882 |
| Omeprazole | 220 | $2,594 |
| Sucralfate | 43 | $2,081 |
| Esomeprazole Magnesium | 38 | $1,923 |
| Budesonide DrBudesonide | 12 | $1,621 |
| Colesevelam Hcl | 18 | $1,187 |
| Lubiprostone | 15 | $987 |
| Famotidine | 45 | $916 |
| Dicyclomine Hcl | 29 | $674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $206 | $73,78713 claims |
| AbbVieLinzess | $4,631 | $52,07238 claims |
| AstraZenecaNexium | $39 | $2,88211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.
Other adult health in Southlake
- Misty SheddAllen$863K
- Melodie YoungDallas$700K
- Cynthia BedellPlano$168K
- Elizabeth Wedberg SivamAustin$71K
- Mary SalazarSan Antonio$68K
- Eric KlappholzDallas$44K
- Christin TouchetKingwood$43K
- Yulia LyuboslavskyAustin$36K
- Meghan MurphyAustin$29K
- Sandra CareyGrapevine$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.